Denise G Simons-Morton1, Jeffrey C Chan2, Angela R Kimel3, Peter E Linz4, Cynthia L Stowe5, John Summerson6, Walter T Ambrosius7. 1. Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, 2701 Rockledge Drive, Bethesda, MD 20892, USA. Electronic address: simonsd@nih.gov. 2. Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, 2701 Rockledge Drive, Bethesda, MD 20892, USA. Electronic address: jeffreycchan@gmail.com. 3. Division of Public Health Sciences, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA. Electronic address: angiekimel@gmail.com. 4. Naval Hospital San Diego, Cardiology Department, 34800 Bob Wilson Dr., San Diego, CA 92134, USA. Electronic address: peter.linz@mercyships.org. 5. Division of Public Health Sciences, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA. Electronic address: cstowe@wakehealth.edu. 6. Division of Public Health Sciences, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA. Electronic address: jsummers@wakehealth.edu. 7. Division of Public Health Sciences, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA. Electronic address: wambrosi@wakehealth.edu.
Abstract
BACKGROUND: Prior studies found that some groups have lower genetic consent rates than others. Participant consent for genetic studies enables randomized trials to examine effects of interventions compared to control in participants with different genotypes. METHODS: Unadjusted and multivariate associations between genetic consent rates and participant, study, and consent characteristics in 9573 participants approached for genetics consent in the multicenter Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which used a layered genetics consent. RESULTS:Eighty-nine percent of eligible participants consented to genetic studies ("Any Consent") and 64.7% consented to studies of any genes by any investigator ("Full Consent"), with similar rates in randomized groups. Controlling for multiple characteristics, African-Americans had lower consent rates than others (Any Consent Odds Ratio, OR = 0.62, p = 0.0004; Full Consent OR = 0.67, p < 0.0001). Those with high school or higher education level had higher rates than less than high school graduates (Full Consent ORs 1.41-1.69, p-values < 0.0001). Consent rates were lower when genetics consent was separate from the main trial consent on the same day (Any Consent OR 0.30; Full Consent OR 0.52, p values < 0.0001) or on a subsequent day (Any Consent OR 0.70, p = 0.0022; Full Consent OR 0.76, p = 0.0002). CONCLUSION: High rates of consent for genetic studies can be obtained in complex randomized trials, with lower consent rates in African-Americans, in participants with less than high-school education, and for sharing samples with other investigators. A genetics consent separated from the main trial consent was associated with lower consent rates. Published by Elsevier Inc.
RCT Entities:
BACKGROUND: Prior studies found that some groups have lower genetic consent rates than others. Participant consent for genetic studies enables randomized trials to examine effects of interventions compared to control in participants with different genotypes. METHODS: Unadjusted and multivariate associations between genetic consent rates and participant, study, and consent characteristics in 9573 participants approached for genetics consent in the multicenter Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which used a layered genetics consent. RESULTS: Eighty-nine percent of eligible participants consented to genetic studies ("Any Consent") and 64.7% consented to studies of any genes by any investigator ("Full Consent"), with similar rates in randomized groups. Controlling for multiple characteristics, African-Americans had lower consent rates than others (Any Consent Odds Ratio, OR = 0.62, p = 0.0004; Full Consent OR = 0.67, p < 0.0001). Those with high school or higher education level had higher rates than less than high school graduates (Full Consent ORs 1.41-1.69, p-values < 0.0001). Consent rates were lower when genetics consent was separate from the main trial consent on the same day (Any Consent OR 0.30; Full Consent OR 0.52, p values < 0.0001) or on a subsequent day (Any Consent OR 0.70, p = 0.0022; Full Consent OR 0.76, p = 0.0002). CONCLUSION: High rates of consent for genetic studies can be obtained in complex randomized trials, with lower consent rates in African-Americans, in participants with less than high-school education, and for sharing samples with other investigators. A genetics consent separated from the main trial consent was associated with lower consent rates. Published by Elsevier Inc.
Authors: Anke-Hilse Maitland-van der Zee; Eric Boerwinkle; Donna K Arnett; Barry R Davis; Catherine Leiendecker-Foster; Michael B Miller; Olaf H Klungel; Charles E Ford; John H Eckfeldt Journal: Am Heart J Date: 2007-01 Impact factor: 4.749
Authors: Stephen E Kimmel; Benjamin French; Jeffrey L Anderson; Brian F Gage; Julie A Johnson; Yves D Rosenberg; Nancy L Geller; Scott E Kasner; Charles S Eby; Jungnam Joo; Michael D Caldwell; Samuel Z Goldhaber; Robert G Hart; Denise Cifelli; Rosemary Madigan; Colleen M Brensinger; Suzanne Goldberg; Robert M Califf; Jonas H Ellenberg Journal: Am Heart J Date: 2013-07-12 Impact factor: 4.749
Authors: Jose C Florez; Kathleen A Jablonski; Nick Bayley; Toni I Pollin; Paul I W de Bakker; Alan R Shuldiner; William C Knowler; David M Nathan; David Altshuler Journal: N Engl J Med Date: 2006-07-20 Impact factor: 91.245
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Rena Conti; David L Veenstra; Katrina Armstrong; Lawrence J Lesko; Scott D Grosse Journal: Med Decis Making Date: 2010-01-04 Impact factor: 2.583
Authors: Tobias Gerhard; Yan Gong; Amber L Beitelshees; Xianyun Mao; Maximilian T Lobmeyer; Rhonda M Cooper-DeHoff; Taimour Y Langaee; Nicholas J Schork; Mark D Shriver; Carl J Pepine; Julie A Johnson Journal: Am Heart J Date: 2008-06-20 Impact factor: 4.749
Authors: Carol A Giffen; Leslie E Carroll; John T Adams; Sean P Brennan; Sean A Coady; Elizabeth L Wagner Journal: Biopreserv Biobank Date: 2015-07-17 Impact factor: 2.300
Authors: Teodora Alexa-Stratulat; Marius Neagu; Anca-Iulia Neagu; Ioana Dana Alexa; Beatrice Gabriela Ioan Journal: Dev World Bioeth Date: 2018-06-22 Impact factor: 2.294
Authors: Jennifer L Young; Julie Mak; Talia Stanley; Michelle Bass; Mildred K Cho; Holly K Tabor Journal: Genet Med Date: 2021-05-10 Impact factor: 8.822
Authors: Hillary T Graham; Daniel M Rotroff; Skylar W Marvel; John B Buse; Tammy M Havener; Alyson G Wilson; Michael J Wagner; Alison A Motsinger-Reif Journal: Front Genet Date: 2016-08-17 Impact factor: 4.599
Authors: Jonathan P Troost; Jennifer Hawkins; Daniel R Jenkins; Debbie S Gipson; Matthias Kretzler; Osama El Shamy; Keith Bellovich; Kalyani Perumal; Zeenat Bhat; Susan Massengill; Susan Steigerwalt; Subramaniam Pennathur; Frank C Brosius; Crystal A Gadegbeku Journal: Kidney Int Rep Date: 2018-06-12